Zacks: Analysts Set $12.00 Target Price for KITOV PHARMA LT/S (NASDAQ:KTOV)

Share on StockTwits

KITOV PHARMA LT/S (NASDAQ:KTOV) has been given an average broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the company, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy recommendation.

Brokerages have set a 12 month consensus price target of $12.00 for the company and are forecasting that the company will post ($0.06) earnings per share for the current quarter, according to Zacks. Zacks has also given KITOV PHARMA LT/S an industry rank of 69 out of 256 based on the ratings given to related companies.

Separately, ValuEngine raised KITOV PHARMA LT/S from a “sell” rating to a “hold” rating in a report on Monday, May 20th.

A hedge fund recently raised its stake in KITOV PHARMA LT/S stock. Morgan Stanley raised its position in shares of KITOV PHARMA LT/S (NASDAQ:KTOV) by 79.8% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 58,240 shares of the company’s stock after purchasing an additional 25,840 shares during the period. Morgan Stanley owned 0.37% of KITOV PHARMA LT/S worth $55,000 as of its most recent SEC filing. 0.48% of the stock is currently owned by institutional investors and hedge funds.

KTOV stock traded up $0.02 during trading hours on Friday, hitting $0.82. 948 shares of the stock traded hands, compared to its average volume of 367,967. The stock has a 50-day simple moving average of $0.80 and a 200 day simple moving average of $0.98. KITOV PHARMA LT/S has a one year low of $0.56 and a one year high of $2.92. The company has a market cap of $12.86 million, a P/E ratio of 2.15 and a beta of 3.61. The company has a current ratio of 1.99, a quick ratio of 2.57 and a debt-to-equity ratio of 0.01.

About KITOV PHARMA LT/S

Kitov Pharma Ltd, through its subsidiaries, operates as a development stage biopharmaceutical company in Israel. It develops combination drugs for the simultaneous treatment of pain caused by osteoarthritis and hypertension. The company's lead drug candidate is KIT-302, a fixed dosage combination product based on the generic drugs celecoxib and amlodipine besylate that has completed its Phase III clinical study.

Featured Story: Arbitrage

Get a free copy of the Zacks research report on KITOV PHARMA LT/S (KTOV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for KITOV PHARMA LT/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KITOV PHARMA LT/S and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.